The Effects of Oral Pentoxifylline on the Prevention of Contrast-Induced Nephropathy in Patients with Chronic Kidney Disease and Normal Renal Function: A Randomized Clinical Trial:

Abstract

Introduction: Finding preventive methods for Contrast-Induced Nephropathy (CIN) is essential for reducing the burden of complications. In this context, anti-oxidant agents such as pentoxifylline can be viable options. This study aimed to determine the effects of oral pentoxifylline on the prevention of contrast induced nephropathy in patients undergoing angiography. Methods and Results: In this randomized clinical trial 96 patients with chronic kidney disease (CKD) and 96 subjects with normal renal function were included and randomly assigned to receive either pentoxifylline or placebo. The Incidence of CIN was determined and compared between the groups. The incidence of CIN in healthy subjects receiving pentoxifylline or placebo was 4 (8.3%) and 2 (4.16%), respectively. (P-value = 1). The incidence of CIN in patients with CKD in the pentoxifylline and placebo group was 5 (10.41%) and 12 (25%) respectively. (P-value = 0.58). Conclusion: According to the obtained results, there was no difference between patients with CKD and those with normal renal function in terms of the pentoxifylline effects on the prevention of Contrast Induced Nephropathy.